Industry Looks At IRA Drawbacks And Silver Linings

Drug Pricing Changes Were Top Of Mind At J.P. Morgan

Industry leaders are concerned about the outlook for small molecule drugs in particular, but execs at the J.P. Morgan Healthcare Conference were also optimistic there could be chances to shape the implementation of certain policies.

two couple are showing half full and half empty side of water glass with their fingers
Industry Looking For Upsides From The IRA

One of the biopharma industry’s biggest worries has been how the Inflation Reduction Act (IRA) will impact US drug pricing and consequently innovation over the long term. So it was expected to be a key topic for one of the industry’s biggest meetings, the J.P. Morgan Healthcare Conference. But while the lack of specifics kept discussion limited during the main stage presentations, executives interviewed by Scrip offered a range of expectations.

Industry leaders have been afraid policies that will allow the US government to negotiate drug prices will have a dire...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Drug Pricing

More from Scrip